However, data regarding its relevance in CML is controversial, as an upregulation of OCT1 in imatinib resistance was shown (White et al., 2006; Engler et al., 2010), while others clearly demonstrated the absence of a OCT1 regulation (Davies et al., 2009; Nies et al., 2014). The gene discussed is SLC22A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.